Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.01 from other evidence | 0.00 |
| cell type Human Protein Atlas | cell type enhanced outside the brain (platelets) | 0.10 |
| chemistry Open Targets | a small-molecule pocket | 0.60 |
| trials ClinicalTrials.gov | no Parkinson's trials on record: an open field | 1.00 |
| literature PubMed | 1 Parkinson's papers of 66 | 0.91 |
| pathways Reactome | 3 pathways; mostly other | 0.30 |
No case: the score is under the bar. Receipt 9387
Sealed predictions
- P2RX1 in dopamine neurons, braak-0.07 (p 0.849) → -0.53 (p 0.145)receipt 9393
Swarm cases
receipt 9393: P2RX1 in dopamine neurons, braak
- power
- full sample -0.54 (p 0.019, n 18), 95% CI -0.81 to -0.10. the interval excludes zero: something may be there, smaller than a half can see.
- confounder
- adjusted for sex: -0.50 (p 0.033, n 18). holds up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.61 (p 0.0075, n 18). not the mix.
- skeptic
- leave-one-out range -0.72 to -0.49, sign flips 0; without severely affected donors -0.54 (p 0.019, n 18). robust.
- cell type
- strongest in oligodendrocytes: -0.59 (p 0.0099, n 18) vs -0.54 in dopamine neurons. proposing oligodendrocytes.
- axis
- no measure beats "tracks Braak Lewy-body stage" for P2RX1 in dopamine neurons.
follow-up registered; not confirmed in substantia nigra, an independent cohort.
follow-up P2RX1 · oligodendrocytes · braak: substantia nigra, an independent cohort: not measured
Receipts
loading the receipts